Drug Profile
Research programme: eye disorder therapies - Charlesson
Alternative Names: CLT-002; CLT-003; CLT-004; CLT-005; CLT-006; CLT-007; CLT-009; CLT-010; CLT-011Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Charlesson LLC
- Developer Charlesson
- Class Peptides; Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors; Vascular endothelial growth factor A modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Intravitreous, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Topical, Drops)